Medical management of adult transsexual persons

Pharmacotherapy

Volumn 32, Issue 1, 2012, Pages 54-66

  Knezevich, Emily L ^a   Viereck, Laura K ^a   Drincic, Andjela T ^b  

^a CREIGHTON UNIVERSITY SCHOOL OF PHARMACY AND HEALTH PROFESSIONS   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cross sex hormone; Gender identity; Gender identity disorder; Hormone therapy; Transgender; Transsexual

Indexed keywords

ESTRADIOL; ESTRADIOL CIPIONATE; ESTRADIOL VALERATE; ESTROGEN; FINASTERIDE; GESTAGEN; GOSERELIN; MEDROXYPROGESTERONE; SPIRONOLACTONE; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE;

ACNE; APPLICATION SITE IRRITATION; BLOOD PRESSURE; BODY FAT; BODY MASS; BREAST AUGMENTATION; BREAST CANCER; CARDIOVASCULAR RISK; CLITORIS HYPERTROPHY; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ESTROGEN THERAPY; FEMALE TO MALE TRANSSEXUAL; GENDER IDENTITY; GONADECTOMY; GYNECOMASTIA; HAIR GROWTH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERKALEMIA; INJECTION SITE REACTION; LIVER ADENOMA; MALE TO FEMALE TRANSSEXUAL; MASTECTOMY; MOOD CHANGE; OSTEOPOROSIS; PATIENT EDUCATION; PATIENT MONITORING; PENIS AMPUTATION; PHARMACIST ATTITUDE; PRACTICE GUIDELINE; PROFESSIONAL KNOWLEDGE; PROSTATE CANCER; PSYCHOLOGIC ASSESSMENT; RECOMMENDED DRUG DOSE; REVIEW; SEX REASSIGNMENT; SIDE EFFECT; SKIN IRRITATION; SKIN MANIFESTATION; TESTOSTERONE BLOOD LEVEL; THROMBOEMBOLISM; TRANSSEXUALISM; VAGINA ATROPHY; VAGINA RECONSTRUCTION; VENOUS THROMBOEMBOLISM; VIRUS HEPATITIS; WEIGHT GAIN;

ADULT; DISEASE MANAGEMENT; FEMALE; GENDER IDENTITY; GONADAL STEROID HORMONES; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; PHARMACISTS; TRANSSEXUALISM;

EID: 84860722840     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/PHAR.1006     Document Type: Review

References (48)

1. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009;94:3132-54.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed, text revision (DSM-IVTR). Washington, DC: American Psychiatric Publishing, Inc., 2000.
3. Gooren LJ. Care of transsexual persons. N Engl J Med 2011;364:1252-7.
4. Meyer WJ III, Bockting W, Cohen-Kettenis P, et al. The Harry Benjamin International Gender Dysphoria Association's standards of care for gender identity disorders, 6th version. Int J Transgenderism 2001;5:1-22. Available from http://www. wpath.org/Documents2/socv6.pdf. Accessed May 1, 2011.
5. World Health Organization. The international statistical classification of diseases and health related problems, 10th ed. Geneva: World Health Organization, 1992.
6. Zucker KJ. Gender identity development and issues. Child Adolesc Psychiatr Clin N Am 2004;13:551-68. (Pubitemid 38748545)
7. Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin Endocrinol 2003;59:409-18. (Pubitemid 37188168)
8. Dahl M, Feldman JL, Goldberg J, Jaberi A. Endocrine therapy for transgender adults in British Columbia: suggested guidelines. Physical aspects of transgender endocrine therapy. Vancouver, British Columbia: Transgender Health Program, 2006. Available from http://transhealth.vch.ca/. Accessed May 1, 2011.
9. Toorians AW, Thomassen MC, Zweegman S, et al. Venous thrombosis and changes of hemostatic variables during crosssex hormone treatment in transsexual people. J Clin Endocrinol Metab 2003;88:5723-9. (Pubitemid 38033041)
10. Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab 2008;93:19-25.
11. Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab 2003;88:3467-73. (Pubitemid 37034478)
12. Dittrich R, Binder H, Cupisti S, Hoffmann I, Beckmann MW, Mueller A. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. Exp Clin Endocrinol Diabetes 2005;113:586-92. (Pubitemid 41810503)
13. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33.
14. Gooren L. Hormone treatment of the adult transsexual patient. Horm Res 2005;64(suppl 2):31-6. (Pubitemid 41665854)
15. Giltay EJ, Gooren LJG. Effect of sex steroid deprivation/ administration on hair growth and skin sebum production in transsexual males and females. J Clin Endocrinol Metab 2000;85:2913-21. (Pubitemid 32269173)
16. McNeill EJM. Management of the transgender voice. J Laryngol Otology 2006;120:521-3. (Pubitemid 44197016)
17. Van Kesteren PJM, Asscheman H, Megens JAJ, Gooren LJG. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol 1997;47:337-42. (Pubitemid 27395966)
18. Yahyaoui R, Esteva I, Haro-Mora JJ, et al. Effect of long-term administration of cross-sex hormone therapy on serum and urinary acid in transsexual persons. J Clin Endocrinol Metab 2008;93:2230-3. (Pubitemid 351831539)
19. Schlatterer K, Yassouridis A, von Werder K, Poland D, Kemper J, Stalla GK. A follow-up study for estimating the effectiveness of a cross-gender hormone substitution therapy on transsexual patients. Arch Sex Behav 1998;27:475-92. (Pubitemid 28457835)
20. Garcia-Malpartida K, Martin-Gorgojo A, Rocha M, Gomez- Balaguer M, Hernandez-Mijares A. Prolactinoma induced by estrogen and cyproterone acetate in a male-to-female transsexual. Fertil Steril 2010;94:1097.e13-15.
21. Perego E, Scaini A, Romano F, Franciosi C, Uggeri F. Estrogen- induced severe acute pancreatitis in a male. J Pancreas 2004;5:353-6. (Pubitemid 41581769)
22. Elbers JMH, Giltay EJ, Teerlink T, et al. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol 2003;58:562-71. (Pubitemid 36566798)
23. Elamin MB, Garcia MZ, Murad MH, Erwin PJ, Montori VM. Effect of sex steroid use on cardiovascular risk in trans-sexual individuals: a systematic review and meta-analysis. Clin Endocrinol 2010;72:1-10.
24. Wilson R, Spiers A, Ewan J, Johnson P, Jenkins C, Carr S. Effects of high dose oestrogen therapy on circulating inflammatory markers. Maturitas 2009;62:281-6.
25. Giltay E, Gooren L, Emeis J, et al. Oral ethinyl estradiol, but not transdermal 17beta-estradiol, increases plasma C-reactive protein levels in man [letter]. Thromb Haemost 2000;84:359-60. (Pubitemid 30601493)
26. Scarabin P, Oger E, Plu-bureau G, on behalf of the Estrogen and Thromboembolism Risk (ESTHER) Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-32. (Pubitemid 36999704)
27. Futterweit W. Endocrine therapy of transsexualism and potential complications of long-term treatment. Arch Sex Behav 1998;27:209-26. (Pubitemid 28169357)
28. Miles C, Green R, Hines M. Estrogen treatment effects on cognition, memory and mood in male-to-female transsexuals. Horm Behav 2006;50:708-17. (Pubitemid 44738852)
29. Asscheman H, Giltay EJ, Megens JA, de Ronde WP, van Trotsenburg MA, Gooren LJ. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2011;164:635-42.
30. Mueller A, Zollver H, Kronawitter D, et al. Body composition and bone mineral density in male-to-female transsexuals during cross-sex hormone therapy using gonadotrophin-releasing hormone agonist. Exp Clin Endocrinol Diabetes 2011;119:95-100.
31. Mueller A, Gooren L. Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2008;159:197-202.
32. Pritchard TJ, Pankowsky DA, Crowe JP, Abdul-Karim FW. Breast cancer in a male-to-female transsexual. JAMA 1988;259:2278-80.
33. U.S. Food and Drug Administration. FDA drug safety communication: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer. Available from http://www.fda.gov/Safety/MedWatch/ SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm258529.htm. Accessed June 9, 2011.
34. Lapauw B, Taes Y, Simoens S, et al. Body composition, volumetric and areal bone parameters in male-to-female transsexual persons. Bone 2008;43:1016-21.
35. Valentini F, Aversa A, Bruzziches R, et al. Characterization of bone mineral density in male-to-female transsexuals receiving treatment for reassignment surgery: 15 years of follow-up. J Mens Health 2008;5:227-33.
36. Bhasin S, Cunningham GR, Hayes FJ, et al. for the Androgen Deficiency Syndromes in Men Guideline Task Force. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2006;91:1995-2010. (Pubitemid 43854972)
37. Seftel A. Review: testosterone replacement therapy for male hypogonadism: III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents. Int J Impot Res 2007;19:2-24. (Pubitemid 46067343)
38. Berg S, Al-Khoury L, Cunningham GR. Testosterone replacement in men. Curr Opin Endocrinol Diabetes Obes 2008;15:364-70.
39. Bhowmick SK, Ricke T, Rettig KR. Sexual precocity in a 16-month-old boy induced by indirect topical exposure to testosterone. Clin Pediatr 2007;46:540-3. (Pubitemid 46920335)
40. Williamson C. Providing care to transgender persons: a clinical approach to primary care, hormones, and HIV management. J Assoc Nurses AIDS Care 2010;21:221-9.
41. Giltay EJ, Hoogeveen EK, Elbert JM, et al. Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females. J Clin Endocrinol Metab 1998; 83:550-3. (Pubitemid 28496538)
42. Herbst JH, Jacobs ED, Finlayson TJ, et al. Estimating HIV prevalence and risk behaviors of transgender persons in the United States: a systematic review. AIDS Behav 2008;12:1-17. (Pubitemid 351143456)
43. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, January 10, 2011;1-166. Available from http:// www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL. pdf. Accessed July 11, 2011.
44. Moreno-Perez O, Escoin C, Serna-Candel C, et al. Risk factors for sexual and erectile dysfunction in HIV-infected men: the role of protease inhibitors. AIDS 2010;34:255-64.
45. Rinaldi M, Cagnacci A, Pansini FE, et al. Neutral effect of prolonged transdermal hormone therapy on liver function of postmenopausal women with chronic active hepatitis. Menopause 2005;12:619-22. (Pubitemid 41362086)
46. Padua MA, Fonseca AM, Deguti MM, et al. Hormone therapy in Brazilian postmenopausal women with chronic hepatitis C: a pilot study. Climacteric 2010;13:179-86.
47. Coombes GB, Reiser J, Paradinas FJ, Burn I. An androgen-associated hepatic adenoma in a trans-sexual. Br J Surg 1978;65:869-70. (Pubitemid 9069748)
48. Abbott Laboratories. AndroGel (testosterone gel) product information. North Chicago, IL; 2011.